Pressure BioSciences, Inc. (PBIO: OTCQB) | Novel Use of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pressure BioSciences, Inc. (PBIO: OTCQB) | Novel Use of Pressure BioSciences' Patented PCT Platform Offers New Insights into Protein Structure and Function, New Tool for Biomarker Discovery and Rational Drug Design Novel Use of Pressure BioSciences' Patented PCT Platform Offers New Insights into Protein Structure and Function, New Tool for Biomarker Discovery and Rational Drug Design

Novel Use of Pressure BioSciences' Patented PCT Platform Offers New Insights into Protein Structure and Function, New Tool for Biomarker Discovery and Rational Drug Design

Advanced Pressure-based Method Unveiled at International Scientific Symposium; Supports Company's Decision to Focus Marketing and Sales Efforts in Spectroscopy Area

PR Newswire

SOUTH EASTON, Mass. , Aug. 1, 2013 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that data supporting important advantages of PBI's powerful and enabling Pressure Cycling Technology ("PCT") platform were presented at the 27 th Annual Symposium of the Protein Society held July 20-23, 2013 in Boston, Massachusetts .

The use of highly sophisticated analytical instrument systems by research scientists worldwide has resulted in a greater understanding of complex biological molecules, including proteins - the "building blocks of life."  One such instrument system, Electron Paramagnetic Resonance ("EPR") spectroscopy, has been shown to provide key information on the structure, flexibility, and function of proteins.  This information is crucial to the development of new and better diagnostics, therapeutics, and vaccines.

At this year's annual Protein Society symposium, researchers from UCLA reported on the development of an improved EPR system based on the use of high pressure.  This novel system combined (for the first time ever) two cutting-edge EPR methods: site directed spin labeling ("SDSL") and double electron-electron resonance ("DEER").  This strategy allowed the investigation of dynamic events in proteins that would be difficult or even impossible to study by conventional EPR technology.

Dr. Wayne L. Hubbell , Distinguished Professor of Chemistry and Biochemistry and Jules Stein Professor of Ophthalmology at UCLA , and senior author of the study, commented: "The study of proteins under pressure by EPR and other spectroscopic techniques, such as Nuclear Magnetic Resonance ("NMR"), has the potential to greatly improve our understanding of the structure and function of proteins. This information could subsequently provide new insights into such important areas as biomarker discovery and rational drug design, and play an important role in the discovery process that lies ahead in the exciting field of protein science."

Richard T. Schumacher , President and CEO of PBI, said: "We believe these and other data reported by researchers using pressure-based EPR and NMR systems strongly indicate that PCT can enhance the recovery, detection, and measurement of proteins from a wide variety of samples. In turn, this information has the potential to help accelerate the design and manufacture of new and better diagnostics, therapeutics, and vaccines.  We further believe that the advantages of pressure-based spectroscopic methods are just now beginning to be realized by scientists, and that as the body of data continues to grow from high pressure-based spectroscopic studies, that PBI has the potential to become a major provider of high pressure equipment into the exciting and growing spectroscopy area."

About the Protein Society

The Protein Society is a not-for-profit scientific and educational membership organization.  It was founded to encourage the development and dissemination of knowledge in all aspects of the study of protein molecules, the "building blocks of life". It does so through its many programs, including its meetings, awards, publications, and committee outreach programs. The Society's members work in academia, foundations, institutes, industry, and in government agencies around the world.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (NASDAQ: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT").  PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for forensics, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, histology, and counter-bioterror applications.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, without limitation, statements regarding the presentation by Dr. Hubbell and his team at the 27 th Annual Symposium of the Protein Society; the reported benefits of high pressure-based spectroscopic techniques, including EPR (including SDSL combined with DEER), NMR, and other spectroscopic methods; that the new pressure-based EPR data support the Company's decision to focus its marketing and sales efforts in the spectroscopy area; that the use of highly sophisticated analytical instrument systems by research scientists worldwide has resulted in a greater understanding of complex biological molecules, including proteins; that this greater understanding of proteins could provide new insights into such important areas as biomarker discovery and rational drug design, and play an important role in the discovery process that lies ahead in the exciting field of protein science; that pressure-based EPR and NMR can offer new insights into protein structure and function; that data reported by researchers using pressure-based EPR and NMR systems strongly indicate that PCT can enhance the recovery, detection, and measurement of proteins from a wide variety of samples, and that this information has the potential to help accelerate the design and manufacture of new and better diagnostics, therapeutics, and vaccines; that the advantages of pressure-based spectroscopic methods are just now beginning to be realized by scientists, and that as the body of data continues to grow from high pressure-based spectroscopic studies, that PBI has the potential to become a major provider of high pressure equipment into the exciting and growing spectroscopy area; and the estimated size of the life sciences sample preparation market. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT-based product line; changes in customer's needs and technological innovations; the Company's and its strategic partners/distributors sales forces may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods; that other researchers may not be able to replicate the data reported or see the advantages of using the Company's PCT platform in the studies mentioned; and if actual operating costs are higher than anticipated, or revenues from product sales are less than anticipated, the Company may need additional capital beyond August 2013 . Further, given the uncertainty in the capital markets and the current status of the Company's product development and commercialization activities, there can be no assurance that the Company will secure the additional capital necessary to fund its operations beyond August 2013 on acceptable terms, if at all.  These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 , and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following link: www.pressurebiosciences.com

Investor Contacts:
Richard T. Schumacher , President and CEO, PBI (508) 230-1828 (T)
Tim Connor , Managing Director, Benchmark Advisory (858) 568-7059 (T)

SOURCE Pressure BioSciences, Inc.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 39

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 97

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 97

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 196

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 64

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 247

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 119

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 93

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Freshpet's P/E Ratio: A Comprehensive Overview

Updated Category News Views 197

Understanding the Current P/E Ratio of Freshpet As we analyze the current trading performance of Freshpet Inc. (NASDAQ: FRPT), the shares are currently priced at $54.50, marking an increase of 0.70% in today’s session. Over the past month, there has been a slight rise of 0.88%. However, a significant decline of 58.54% has been noted over the last year. For shareholders,...

Continue Reading
Hilb Group Expands Footprint with New Property Acquisition

Updated Category News Views 108

Hilb Group Expands Footprint with New Property Acquisition The Hilb Group has announced an exciting addition to its portfolio through the acquisition of a property and casualty business based in Alabama. This strategic move reinforces the company's commitment to enhancing its presence in the property and casualty insurance sector. Strategic Growth Through Acquisitions In...

Continue Reading
Insurance Bad Faith: Navigating California's Rigorous Laws

Updated Category News Views 7

Understanding What Constitutes Bad Faith Insurance What does it really mean when an insurer acts in "bad faith"? Well, the legal standard doesn't leave much wiggle room in California. These aren't just bad outcomes; we're talking about conduct that defies what's reasonable under state law. Demián I. Oksenendler, a seasoned bad faith attorney, shed some light on this in a...

Continue Reading
Macrovey's Triumphant Journey at the Supply Chain Awards

Updated Category News Views 83

Macrovey's Nomination for Prestigious Supply Chain Awards Macrovey, a frontrunner in supply chain technology, is excited to share that it has been nominated for three esteemed awards at this year's Supply Chain Excellence Awards. This honor reflects the company’s ongoing dedication to improving efficiency and driving innovation in the supply chain field. Recognized...

Continue Reading
ITT Achieves Moody's Ratings Upgrade and Financial Growth Insights

Updated Category News Views 91

Moody's Ratings Upgrade for ITT Inc. ITT Inc. recently celebrated a significant achievement as Moody’s Ratings upgraded the company's credit rating from Baa2 to Baa1. This positive development underlines the company’s solid financial performance and growth strategies. The upgrade signals confidence in ITT’s ability to maintain and enhance profitability while...

Continue Reading